Background: Hand osteoarthritis is a common and disabling chronic joint disease with a lack of effective therapies. Emerging evidence suggests the role of local inflammation in causing pain in hand osteoarthritis. Corticosteroids are potent anti-inflammatory drugs used in many rheumatic diseases. The aim of this randomised, double-blind, placebo-controlled trial is to determine whether topical corticosteroid reduces pain over 6 weeks in patients with hand osteoarthritis.
Methods: One hundred participants with hand osteoarthritis will be recruited from the community in Melbourne, Australia, and randomly allocated in a 1:1 ratio to receive either topical Diprosone OV or placebo ointment administered 3 times daily on the painful hand joints for 6 weeks. The primary outcome is pain reduction (assessed by 100 mm visual analogue scale) at 6 weeks. The secondary outcomes include changes in pain and function assessed using Functional Index for Hand Osteoarthritis, Australian Canadian Osteoarthritis Hand Index, Michigan Hand Outcomes Questionnaire, and tender and swollen joint count at 6 weeks. Adverse events will be recorded. The primary analysis will be by intention to treat, including all participants in their randomised groups.
Discussion: This study will provide high-quality evidence to determine whether topical corticosteroid reduces pain over 6 weeks in patients with hand osteoarthritis, with major clinical and public health importance by informing clinical practice guidelines for the management of hand osteoarthritis and reducing the burden of the disabling disease.
Trial Registration: Australian New Zealand Clinical Trials Registry (ANZCTR), ACTRN12620000599976 . Registered 22 May 2020.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670184 | PMC |
| http://dx.doi.org/10.1186/s12891-021-04921-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Reports of equivalent patient reported outcomes between anatomic total shoulder arthroplasty (aTSA) and reverse total shoulder arthroplasty (rTSA) have contributed to a continued preference of rTSA. While many surgeons believe the best aTSA outcome can outperform the best rTSA outcome, this has not yet been demonstrated in the literature. The purpose of this study is to investigate the outcome characteristics of aTSA and rTSA patients who perceive their shoulder is close to normal, with the hypothesis that aTSA patients will outperform rTSA patients.
View Article and Find Full Text PDFCase Series: Free vascularized costochondral grafts in upper extremity reconstruction.
Front Surg
February 2025
Department of Plastic, Reconstructive, Aesthetic and Hand Surgery, University Hospital Basel, Basel, Switzerland.
Introduction: Costochondral grafting is well-known reconstructive option for the temporomandibular joint. In the upper extremity, non-vascularized costochondral grafts have been used for radial head reconstruction, for osteoarthritis of the trapeziometacarpal joint and proximal pole reconstruction of the scaphoid. Evidence suggests that vascularization of bone grafts lead to a higher union rate and a faster time to union.
View Article and Find Full Text PDFAn overview of obesity-related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes.
Diabetes Obes Metab
March 2025
Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München, University of Leipzig and University Hospital Leipzig, Leipzig, Germany.
Obesity is a highly prevalent chronic multisystem disease associated with shortened life expectancy due to a number of adverse health outcomes. Epidemiological data link body weight and parameters of central fat distribution to an increasing risk for type 2 diabetes, hypertension, fatty liver diseases, cardiovascular diseases including myocardial infarction, heart failure, atrial fibrillation, stroke, obstructive sleep apnoea, osteoarthritis, mental disorders and some types of cancer. However, the individual risk to develop cardiometabolic and other obesity-related diseases cannot entirely be explained by increased fat mass.
View Article and Find Full Text PDFCADOR (Capsaicin in neuropathic-like pain in digital osteoarthritis) study protocol: a multicentre randomised parallel-group trial.
BMJ Open
March 2025
Department of Rheumatology, CHU Clermont-Ferrand, Clermont-Ferrand, France
Introduction: It is common for finger pain in hand osteoarthritis (HOA) to display a neuropathic component. Non-steroidal anti-inflammatory drugs (NSAIDs) and conventional analgesics are not very effective in relieving this neuropathic-like pain. Capsaicin, a compound extracted from chilli peppers, is approved for the management of localised neuropathic pain.
View Article and Find Full Text PDFThe association between dyslipidemia and hand osteoarthritis: a systematic review and meta-analysis.
Clin Rheumatol
March 2025
Department of Orthopedics, Wan Fang Hospital, Taipei Medical University, Taipei, 116, Taiwan.
Background: Hand osteoarthritis (HOA) is a prevalent degenerative joint disease, with emerging evidence suggesting metabolic factors, including dyslipidemia, play a role in its pathogenesis. Dyslipidemia components, including low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides, may contribute to cartilage damage and inflammation in hand joints, though robust evidence is limited.
Method: A systematic review and meta-analysis were conducted using PubMed, Embase, and Web of Science to identify case-control and cohort studies examining the association between dyslipidemia and HOA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!